Hypophosphatemia predicts a failure to recover from adefovir-related renal injury after dose reduction in lamivudine-resistant hepatitis B patients
- 3 February 2017
- journal article
- Published by Wiley in Hepatology Research
- Vol. 47 (12) , 1272-1281
Abstract
Patients aged ≥50 years are predisposed to adefovir-related renal injury and switching to another antiviral agent rather than adefovir dose reduction is recommended when hypophosphatemia is observed.Keywords
This publication has 25 references indexed in Scilit:
- Hypophosphatemic Osteomalacia Due to Drug-induced Fanconi's Syndrome Associated with Adefovir Dipivoxil Treatment for Hepatitis BInternal Medicine, 2014
- Two Cases of Hypophosphatemic Osteomalacia After Long-term Low Dose Adefovir Therapy in Chronic Hepatitis B and Literature ReviewJournal of Bone Metabolism, 2014
- Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predispositionJournal of Clinical Pharmacy and Therapeutics, 2013
- Drug safety evaluation of adefovir in HBV infectionExpert Opinion on Drug Safety, 2011
- Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide AnaloguesHepatology, 2010
- Efficacy of entecavir treatment for lamivudine‐resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?Journal of Gastroenterology and Hepatology, 2009
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- Long-term safety of lamivudine treatment in patients with chronic hepatitis BGastroenterology, 2003
- Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis BClinical Infectious Diseases, 2003
- Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral TherapyA Randomized Controlled TrialJAMA, 1999